Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.

European Heart Journal
Thomas F Lüscherdal-VESSEL Investigators

Abstract

High-density lipoprotein cholesterol (HDL-C) is inversely associated with cardiovascular (CV) events and thus an attractive therapeutic target. However, in spite of marked elevations in HDL-C, the first cholesterol transport protein (CETP) inhibitor torcetrapib raised blood pressure (BP), impaired endothelial function, and increased CV mortality and morbidity. Dalcetrapib is a novel molecule acting on CETP with a different chemical structure to torcetrapib. As HDL stimulates nitric oxide (NO), suppresses inflammation, and exerts protective CV effects, we investigated the effects of dalcetrapib on endothelial function, blood pressure, inflammatory markers, and lipids in patients with, or at risk of, coronary heart disease (CHD) in a double-blind randomized placebo-controlled trial (clinicaltrials.gov number NCT00655538). Patients with target low-density lipoprotein cholesterol (LDL-C) levels received dalcetrapib 600 mg/day or placebo for 36 weeks on top of standard therapy (including statins). The primary outcome measures were the change from baseline of flow-mediated dilatation (%FMD) of the right brachial artery after 5 min of cuff occlusion at 12 weeks and the 24 h ambulatory blood pressure monitoring (ABPM) at week 4. Second...Continue Reading

References

Feb 23, 1995·The American Journal of Cardiology·T J AndersonP Ganz
Apr 1, 1997·Heart·M J MullenC J Jones
Dec 31, 1997·The American Journal of Cardiology·S Kinlay, P Ganz
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Dec 18, 2001·Arteriosclerosis, Thrombosis, and Vascular Biology·D M HerringtonG L Burke
Aug 7, 2002·Circulation·Julian P J HalcoxArshed A Quyyumi
Jan 4, 2003·The Journal of Biological Chemistry·Chieko MineoPhilip W Shaul
Nov 6, 2003·JAMA : the Journal of the American Medical Association·Steven E NissenRichard Kerensky
Apr 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·Brian G DrewBronwyn A Kingwell
Jan 12, 2005·Journal of Hypertension·John DeanfieldUNKNOWN Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension
Jan 22, 2005·Journal of Hypertension·Hanspeter BrunnerUNKNOWN Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension
Apr 22, 2005·The American Journal of Cardiology·Jan Albert KuivenhovenJohn J P Kastelein
Mar 28, 2007·The New England Journal of Medicine·Steven E NissenUNKNOWN ILLUSTRATE Investigators
Sep 28, 2007·The New England Journal of Medicine·Philip BarterUNKNOWN Treating to New Targets Investigators
Nov 7, 2007·The New England Journal of Medicine·Philip J BarterUNKNOWN ILLUMINATE Investigators
Sep 16, 2008·Thrombosis Research·Frank HermannThomas F Lüscher
May 21, 2009·Journal of Cardiovascular Pharmacology·Eileen BlasiJoan Keiser
Jul 7, 2009·The American Journal of Cardiology·Evan A SteinJohn J P Kastelein
Sep 17, 2009·JAMA : the Journal of the American Medical Association·Marietta CharakidaJohn E Deanfield
Dec 5, 2009·American Heart Journal·Gregory G SchwartzUNKNOWN dal-OUTCOMES Committees and Investigators
Jan 26, 2010·European Heart Journal·Evan A SteinJennifer G Robinson
Nov 19, 2010·The New England Journal of Medicine·Christopher P CannonUNKNOWN Determining the Efficacy and Tolerability Investigators
Nov 23, 2010·Journal of Inflammation·Phoebe A StapletonJefferson C Frisbee

❮ Previous
Next ❯

Citations

Dec 18, 2012·Current Atherosclerosis Reports·Willibald Hochholzer, Robert P Giugliano
Sep 20, 2012·Current Cardiology Reports·Daniel B LarachDaniel J Rader
May 10, 2013·Clinical Pharmacokinetics·Amir Hooshang Mohammadpour, Fatemeh Akhlaghi
Mar 19, 2013·Biochemical Pharmacology·Kyriakos E KypreosIordanis Karagiannides
Nov 7, 2012·The New England Journal of Medicine·Gregory G SchwartzUNKNOWN dal-OUTCOMES Investigators
May 16, 2012·European Heart Journal·Thomas F LüscherWilliam Wijns
Jan 4, 2013·European Heart Journal·Marietta CharakidaJohn Eric Deanfield
Jul 4, 2013·European Heart Journal·Marietta CharakidaJohn E Deanfield
Sep 10, 2013·European Heart Journal·Guenther SilbernagelWinfried März
Oct 5, 2013·European Heart Journal·Thomas F Lüscher
May 7, 2013·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Thimoteus SpeerDanilo Fliser
Apr 21, 2012·Current Opinion in Lipidology·Bernd Hewing, Edward A Fisher
Sep 27, 2012·Current Opinion in Lipidology·Raphaël Duivenvoorden, Zahi A Fayad
Feb 22, 2012·International Journal of Clinical Practice·A S WierzbickiA Viljoen
Aug 8, 2012·Circulation·Andreas J FlammerAmir Lerman
May 3, 2012·Journal of Lipid Research·Philip J Barter, Kerry-Anne Rye
Jan 7, 2014·PloS One·Kevin G McLurePeter R Young
May 17, 2014·PloS One·Monica GomaraschiLaura Calabresi
Oct 12, 2012·Drug Design, Development and Therapy·Alyse S Goldberg, Robert A Hegele
Aug 24, 2012·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Mariarita PuntoniTiziana Sampietro
Jan 16, 2014·Annual Review of Medicine·Daniel J Rader, Emil M deGoma
Jan 5, 2014·European Heart Journal·S Gielen, U Landmesser
Apr 30, 2014·Current Atherosclerosis Reports·Davide NotoMaurizio R Averna
Jun 22, 2014·Current Cardiology Reports·Carlos G Santos-Gallego, Robert S Rosenson
Jun 22, 2014·Cardiovascular Research·Alan T RemaleyAlberico L Catapano
Aug 26, 2014·Cardiovascular Ultrasound·Rosa Maria BrunoLorenzo Ghiadoni
Nov 30, 2014·Endocrinology and Metabolism Clinics of North America·Carlos G Santos-GallegoRobert S Rosenson
Jun 4, 2014·Current Atherosclerosis Reports·Angela PirilloAlberico Luigi Catapano
Aug 21, 2013·Nature Reviews. Cardiology·Antonio M Gotto, Jennifer E Moon
Jan 30, 2016·Expert Opinion on Biological Therapy·Marcos G ValerioWilbert S Aronow
May 27, 2014·Expert Opinion on Investigational Drugs·Gerald H Tomkin, Daphne Owens
Oct 31, 2014·Expert Opinion on Emerging Drugs·Matilda FlorentinMoses S Elisaf
Jun 26, 2012·Expert Opinion on Investigational Drugs·Amanda J Hooper, John R Burnett
Oct 8, 2013·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Pablo Corral, Laura Schreier
Aug 21, 2012·The Canadian Journal of Cardiology·Pamela M Katz, Lawrence A Leiter

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.